Background
Cristina Adriana Popa
High or Low Phosphate? Are we Missing the ...

This week, we will discuss the phosphate targets in dialysis. Are you aiming for HIgh or Low?

High or Low Phosphate? Are we Missing the (P)oint?
Background
Brian Rifkin
Mind The Gap: When eGFR Creatinine and Cystatin ...

This week, we will discuss the clinical significance of eGFRdiff, the difference in eGFRcys (cystatin C) and eGFRcr (creatinine).

Mind The Gap: When eGFR Creatinine and Cystatin C Disagree
Background
Cristina Adriana Popa
A dose of CONFIDENCE: Building evidence for ...

This week, we will discuss how the CONFIDENCE trial gets nephrology closer to the magic CKD polypill of CKD.

A dose of CONFIDENCE: Building evidence for finerenone-empagliflozin synergy in diabetic kidney disease
Background
swapnil hiremath
From single shots to strategy: How CAPTIVATE is ...

Summary of the CAPTIVATE platform which will be a twitter spaces discussion

From single shots to strategy: How CAPTIVATE is reframing the NephTrials playbook
Background
Cristina Adriana Popa
Are E-Nudges Enough to Push Guideline-Based CKD ...

This week, we will discuss a registry trial: can a nationwide nudge fix a CKD treatment gap?

Are E-Nudges Enough to Push Guideline-Based CKD Therapy?

ACTIVE

Longer is Better, Except when it is Not, Really: Hemodialysis Edition

Longer is Better, Except when it is Not, Really: Hemodialysis Edition

The ACTIVE trial tested the hypothesis that longer dialysis would be better for quality of life. Sadly, this did not turn out to be the case. Is the end of longer being better? Join us as we dissect the study at the next NephJC.